@article{oai:nagasaki-u.repo.nii.ac.jp:00026875,
 author = {Hashizume, Junya and Shiojiri, Kyohei and Ryu, Emi and Kawauchi, Yuki and Hasegawa, Kyoko and Ezaki, Nozomi and Yamashita, Haruna and Ishii, Koji and Harasawa, Hitomi and Nakamura, Tadahiro and Sasaki, Hitoshi and Kodama, Yukinobu},
 issue = {8},
 journal = {Biological and Pharmaceutical Bulletin},
 month = {Aug},
 note = {Naldemedine (NAL), a peripherally acting μ-opioid receptor antagonist, is effective for opioid-induced constipation (OIC). However, diarrhea is the most common adverse event. We investigated the incidence of NAL-induced diarrhea in patients who started NAL at Nagasaki University Hospital between June 2017 and March 2019. Predictors of NAL-induced diarrhea were analyzed using a multivariate logistic regression model. Two hundred and forty-two patients were included in the present study, and NAL-induced diarrhea was observed in 17.8% (43 patients). The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or longer before the initiation of NAL (odds ratio (OR): 2.20, 95% confidence interval (95% CI): 1.04–4.64, p = 0.039), the combination of a laxative (OR: 2.22, 95%CI: 1.03–4.81, p = 0.042), and the combination of CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95%CI: 1.02–7.67, p = 0.045) as risk factors. Therefore, the development of diarrhea needs to be considered in patients with these risk factors. Furthermore, diarrhea may be controlled by the initiation of NAL within 7 d of opioid analgesics and, where possible, the discontinuation of or change in the combination of moderate or strong CYP3A4 inhibitors., Biological and Pharmaceutical Bulletin, 44(8), pp. 1081-1087; 2021},
 pages = {1081--1087},
 title = {Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine},
 volume = {44},
 year = {2021}
}